Inducing Immunity Where It Matters: Orthotopic HPV Tumor Models and Therapeutic Vaccinations.

ABSTRACT: Anogenital and oropharyngeal cancers caused by human papillomavirus (HPV) infections account for 4.5% of all cancer cases worldwide. So far, only the initial infection with selected high-risk types can be prevented by prophylactic vaccination. Already existing persistent HPV infections, however, can currently only be treated by surgical removal of resulting lesions. Therapeutic HPV vaccination, promoting cell-based anti-HPV immunity, would be ideal to eliminate and protect against HPV-induced lesions and tumors. A multitude of vaccination approaches has been tested to date, many of which led to high amounts of HPV-specific T cells in vivo. However, growing evidence suggests that not the induction of systemic but of local immunity is paramount for tackling mucosal infections and tumo

SUBMITTER: Zottnick S 

PROVIDER: S-EPMC7457000 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature